Current Appointments & Affiliations
Instructor in the Department of Medicine
·
2020 - Present
Medicine, Hematologic Malignancies and Cellular Therapy,
Medicine
Member of the Duke Cancer Institute
·
2022 - Present
Duke Cancer Institute,
Institutes and Centers
Recent Publications
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
Journal Article J Clin Oncol · April 20, 2020 PURPOSE: Patients with acute myeloid leukemia (AML) in remission remain at risk for relapse even after allogeneic hematopoietic cell transplantation (alloHCT). AML measurable residual disease (MRD) status before alloHCT has been shown to be prognostic. Whe ... Full text Link to item CiteProspective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell Transplantation.
Journal Article J Clin Oncol · December 20, 2017 Purpose Several open-label randomized studies have suggested that in vivo T-cell depletion with anti-T-lymphocyte globulin (ATLG; formerly antithymocyte globulin-Fresenius) reduces chronic graft-versus-host disease (cGVHD) without compromising survival. We ... Full text Link to item CiteAllogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia.
Journal Article Biol Blood Marrow Transplant · May 2017 Allogeneic hematopoietic cell transplantation (HCT) is potentially curative for patients with chronic myelomonocytic leukemia (CMML); however, few data exist regarding prognostic factors and transplantation outcomes. We performed this retrospective study t ... Full text Link to item CiteEducation, Training & Certifications
Duke University, School of Medicine ·
1989
M.D.